Hydroxychloroquine treatment for Recurrent Pregnancy Loss: a randomized double-blind placebo-controlled trial

Hvidovre Hospital0 个研究点目标入组 186 人2024年7月3日

概览

暂无简介。

注册库

who.int

开始日期

2024年7月3日

结束日期

待定

最后更新

去年

研究类型

Interventional clinical trial of medicinal product

发起方

•\= 4 confirmed consecutive pregnancy losses prior to gestational age 22\+0 in women with unexplained recurrent pregnancy loss (RPL), \= 3 confirmed consecutive pregnancy losses prior to gestational age 22\+0 in women with unexplained RPL with minimum one second trimester loss

•Age \< 18 years or \> 40 years, Previous HCQ treatment in relation to conceive, \> 1 previous live birth., Previous participation in current study., Prominent uterine abnormalities detected by hysterosalpingography/hysteroscopy or hydrosonography, Known prominent chromosome abnormalities for the couple trying to conceive, A menstrual cycle \< 23 days or \> 35 days if the pregnancy is conceived naturally. If the woman received fertility treatment the menstrual cycle has no consequence., Detection of positive lupus\-anticoagulant or positive IgG/IgM for anticardiolipin\-antibodies (\=10 GPL kU/l, measured at the same laboratories at the Capital Region of Denmark) or plasma homocysteine \=25 microgram/l by repeated measurements 12 weeks apart before the pregnancy., Positive HIV test or test indicating chronic hepatitis B or C., Psoriasis, retinopathic or serious hearing deficiency (contraindication for treatment with HCQ), Current chronic disease implicating a constant consumption of immunomodulatory medicine or medicine potentially harmful to the pregnancy/embryo, Hgb \= 6\.5 mmol/L, leucocytes \< 3\.5 E9/L, thrombocytes \< 145 E9/L by the time of inclusion